0HF3 Stock Chart & Stats
$311.72
$7.08(2.27%)
At close: 4:00 PM EDT
$311.72
$7.08(2.27%)
Day’s Range― - ―
52-Week Range$245.77 - $381.28
Previous CloseN/A
Volume682.00
Average Volume (3M)339.00
Market Cap
$60.57B
Enterprise Value$63.93K
Total Cash (Recent Filing)$2.82B
Total Debt (Recent Filing)$11.72B
Price to Earnings (P/E)23.7
Beta0.51
Next Earnings
Nov 11, 2026EPS Estimate
4.59Next Dividend Ex-DateN/A
Dividend Yield0.75%
Share Statistics
EPS (TTM)13.52
Shares Outstanding194,561,070
10 Day Avg. Volume126
30 Day Avg. Volume339
Financial Highlights & Ratios
PEG Ratio7.05
Price to Book (P/B)40.17
Price to Sales (P/S)0.19
P/FCF Ratio18.89
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$367.88Price Target Upside18.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)17.83
Revenue Forecast (FY)$337.27B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash FlowCencora's TTM free cash flow of roughly $4.1B constitutes a durable strength: the high absolute FCF level supports ongoing debt service, opportunistic buybacks, and incremental M&A or reinvestment. Over 2–6 months this cash generation provides flexibility versus peers in a low-margin industry.
Specialty And GLP-1-driven Revenue MixA larger share of specialty therapies and GLP-1 sales shifts the revenue mix toward higher-value, service-intensive products. This structural tilt supports persistent gross-profit expansion, deeper commercial services demand, and diversification away from low-margin commodity distribution over the medium term.
Margin Expansion And Operating ExecutionRecent margin expansion and upgraded operating-income guidance reflect durable operational leverage from integration of higher-margin businesses like OneOncology. Sustained execution that raises adjusted operating income guidance signals persistent improvement in mix and cost management rather than a one-off earnings blip.
Bears Say
Elevated Leverage And Balance-sheet SensitivityMaterial leverage in a structurally thin-margin distribution business increases vulnerability to working-capital swings, interest-rate moves, and unexpected cash needs. Even with rebuilt equity, the high debt load constrains strategic flexibility and raises refinancing and covenant risk over the medium term.
Structurally Thin MarginsCencora operates with consistently low gross and net margins typical of distribution. Such a compressed margin profile limits the firm's ability to absorb pricing pressure, rising freight or labor costs, or customer mix shifts, making profitability and cash conversion more sensitive to adverse industry moves.
Acquisition And Interest-cost HeadwindsAcquisitions and related financing have raised net interest expense and integration costs, and the contemplated MWI–Covetrus transaction could materially reduce Other-segment operating income. These structural cost and deal-related headwinds increase execution risk and temper near-term earnings durability.
Cencora News
0HF3 FAQ
What was Cencora’s price range in the past 12 months?
Cencora lowest share price was $245.77 and its highest was $381.28 in the past 12 months.
What is Cencora’s market cap?
Cencora’s market cap is $60.57B.
When is Cencora’s upcoming earnings report date?
Cencora’s upcoming earnings report date is Nov 11, 2026 which is in 96 days.
How were Cencora’s earnings last quarter?
Cencora released its earnings results on Aug 05, 2026. The company reported $4.48 earnings per share for the quarter, beating the consensus estimate of $4.347 by $0.133.
Is Cencora overvalued?
According to Wall Street analysts Cencora’s price is currently Undervalued.
Does Cencora pay dividends?
Cencora pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 0.75%. See more information on Cencora dividends here
What is Cencora’s EPS estimate?
Cencora’s EPS estimate is 4.59.
How many shares outstanding does Cencora have?
Cencora has 194,561,070 shares outstanding.
What happened to Cencora’s price movement after its last earnings report?
Cencora reported an EPS of $4.48 in its last earnings report, beating expectations of $4.347. Following the earnings report the stock price went up 3.216%.
Which hedge fund is a major shareholder of Cencora?
Currently, no hedge funds are holding shares in GB:0HF3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$367.88 (18.01% Upside)
$367.88 (18.01% Upside)
Blogger Sentiment
Bullish
GB:0HF3 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $2.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.49%
12-Months-Change
Fundamentals
Return on Equity
0.75%
Trailing 12-Months
Asset Growth
14.69%
Trailing 12-Months
Company Description
Cencora
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
0HF3 Company Deck
0HF3 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong execution and durable specialty-driven growth: consolidated revenue and adjusted gross profit growth, margin expansion, double-digit operating income increases, 12% EPS growth, upgraded EPS guidance, significant share repurchases, and robust free cash flow. Key drivers included strong U.S. Healthcare Solutions performance (MSOs and specialty), International momentum, and OneOncology outperforming expectations. Headwinds discussed were notable but largely manageable: $2.4B of manufacturer list-price reductions, a prior oncology customer loss, lower mail-order sales, acquisition-related higher operating expenses and increased interest expense, and a potential FY27 earnings headwind from the planned MWI transaction. Overall, the positive operational and financial outcomes and guidance raise outweigh the discrete and partly acquisition-related challenges.View all GB:0HF3 earnings summaries0HF3 Revenue Breakdown
90.55% U.S. Healthcare Solutions
9.45% International Healthcare Solutions
>-0.01% Intersegment eliminations
0HF3 Stock 12 Month Forecast
Average Price Target
$367.88
▲(18.01% Upside)
Technical Analysis
Cardinal Health
―
Henry Schein
―
McKesson
―
Prestige Consumer Healthcare
―
Guardian Pharmacy Services, Inc. Class A
―